AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24824893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1079
Study 24824893 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1079
Study 24824893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1079
Study 23567060 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously + Diphenhydramine 25 mg intravenously
Number of subjects: 120
Study 23567060 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 120
Study 23567060 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide + Diphenhydramine
Number of subjects: 120
Study 22748030 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclectic approach therapy with parental involvement
Number of subjects: 0
Study 22748030 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led treatment
Number of subjects: 0
Study 22748030 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led treatment
Number of subjects: 0
Study 22748030 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 0
Study 17379359 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16-24mg/day)
Number of subjects: 18
Study 17379359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15719316 — intervention group
Group type: EXPERIMENTAL
Intervention: TGDc‐01 PRA
Number of subjects: 225
Study 15719316 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometry
Number of subjects: 225
Study 11834534 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 12
Study 11834534 — intervention group
Group type: COMPARATOR
Intervention: Extracted soy protein diet
Number of subjects: 12
Study 11834534 — intervention group
Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 12
Study 11834534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected to soy protein diet
Number of subjects: 12
Study 11834534 — intervention group
Group type: COMPARATOR
Intervention: Extracted soy protein and casein diets
Number of subjects: 12
Study 9799062 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg once-daily
Number of subjects: 0
Study 9799062 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg divided into 2 doses (twice-daily)
Number of subjects: 0
Study 7542465 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive video education intervention
Number of subjects: 194
Study 7542465 — intervention group
Group type: COMPARATOR
Intervention: Culturally dissimilar video education intervention
Number of subjects: 194
Study 2677721 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day)
Number of subjects: 102
Study 2677721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 2677721 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day) in reactive patients
Number of subjects: 102
Study 2677721 — intervention group
Group type: COMPARATOR
Intervention: Control group in reactive patients
Number of subjects: 102
Study 2677721 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day) in nonreactive patients
Number of subjects: 102
Study 72239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (S.A.S.P.)
Number of subjects: 0
Study 72239 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-A.S.A.)
Number of subjects: 0
Study 72239 — intervention group
Group type: COMPARATOR
Intervention: Sulphapyridine (S.P.)
Number of subjects: 0
Study 31745991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 400 mg
Number of subjects: 0
Study 31745991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 31745991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 31745991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31745991 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 2 mg
Number of subjects: 0
Study 31206639 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit prognostic disclosure (video with explicit disclosure)
Number of subjects: 105
Study 31206639 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure (video without explicit disclosure)
Number of subjects: 105
Study 27859312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting central lymph node metastasis (CLNM)
Number of subjects: 10763
Study 25922846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic drugs and vitamin D3 therapy (Group DM4)
Number of subjects: 145
Study 25922846 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (Group DM3)
Number of subjects: 145
Study 25922846 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group NC)
Number of subjects: 145
Study 24666922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin bolus (hypoglycaemia)
Number of subjects: 10
Study 24666922 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (control episode)
Number of subjects: 10
Study 21246365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and passive physiotherapy methods
Number of subjects: 60
Study 21246365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment methods
Number of subjects: 60
Study 21246365 — intervention group
Group type: COMPARATOR
Intervention: Medication (nonsteroid anti-inflammatory and muscle relaxing medicines)
Number of subjects: 60
Study 19634042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 0
Study 19634042 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin gel 0.025%
Number of subjects: 0
Study 17323096 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel and fibrin sealant
Number of subjects: 165
Study 17323096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no platelet gel and fibrin sealant)
Number of subjects: 165
Study 15247958 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKEnox (n=165): Enox 40 mg i.v. followed by SK 1.5 MU over 20 min, Enox 1 mg/kg s.c. every 12 hours for 5-7 days
Number of subjects: 633
Study 15247958 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKUFH (n=264): Same as ASKEnox plus UFH 1,000 IU/h for 48-72 hours
Number of subjects: 633
Study 15247958 — intervention group
Group type: COMPARATOR
Intervention: SSKUFH (n=204): SK 1.5 MU/60 min plus UFH 1,000 IU/h for 48-72 hours
Number of subjects: 633
Study 15247958 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKEnox
Number of subjects: 633
Study 15247958 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKUFH
Number of subjects: 633
Study 15247958 — intervention group
Group type: COMPARATOR
Intervention: SSKUFH
Number of subjects: 633
Study 15247958 — intervention group
Group type: EXPERIMENTAL
Intervention: ASKEnox and ASKUFH
Number of subjects: 633
Study 11746315 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighting methods derived using linear regression on overall quality of life measures.
Number of subjects: 0
Study 11746315 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures for transforming quality of life measures into utility measures.
Number of subjects: 0
Study 9645976 — intervention group
Group type: EXPERIMENTAL
Intervention: CORTI
Number of subjects: 3
Study 9645976 — intervention group
Group type: COMPARATOR
Intervention: SDI
Number of subjects: 3
Study 9645976 — intervention group
Group type: COMPARATOR
Intervention: PICH
Number of subjects: 3
Study 7528302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT (0.1, 0.3, and 1 ng/kg/min) with L-NMMA (30 μg/kg/min)
Number of subjects: 8
Study 7528302 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan (15, 45, and 150 ng/kg/min) with L-NMMA (30 μg/kg/min)
Number of subjects: 8
Study 7528302 — intervention group
Group type: COMPARATOR
Intervention: Saline with L-NMMA (30 μg/kg/min)
Number of subjects: 8
Study 29771966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) ingestion up to 150 mg∙kg‐1 in a progressive-dose regimen for 10 days
Number of subjects: 21
Study 29771966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) ingestion
Number of subjects: 21
Study 26418574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 536 (BB536)
Number of subjects: 56
Study 26418574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24748529 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE) at 150% VO2 peak for 30 minutes
Number of subjects: 8
Study 24748529 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) cycling at 50% VO2 peak for 30 minutes
Number of subjects: 8
Study 23735118 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 0
Study 23735118 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 19690913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90
Study 19690913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90
Study 19690913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19474572 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal repetition in patients with AD
Number of subjects: 130
Study 16968142 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, developmentally oriented, highly individualized intervention over a 2-year period
Number of subjects: 0
Study 16968142 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 45
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (postoperative infusion)
Number of subjects: 45
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (postoperative infusion)
Number of subjects: 45
Study 12719052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (postoperative infusion)
Number of subjects: 45
Study 10805824 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet (total, 50 g; 25 g of soluble fiber and 25 g of insoluble fiber)
Number of subjects: 13
Study 9483708 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially dominant subjects
Number of subjects: 63
Study 9483708 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate men
Number of subjects: 63
Study 9483708 — intervention group
Group type: EXPERIMENTAL
Intervention: End of training
Number of subjects: 63
Study 8347915 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging with twice-daily dosing (group 3)
Number of subjects: 31
Study 8347915 — intervention group
Group type: COMPARATOR
Intervention: Conventional packaging with twice-daily dosing (group 2)
Number of subjects: 31
Study 8347915 — intervention group
Group type: COMPARATOR
Intervention: No change in dosing or packaging (group 1)
Number of subjects: 31
Study 2875927 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (200 mg three times daily)
Number of subjects: 221
Study 2875927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 2875927 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 221
Study 29676824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine with brief behavioural support
Number of subjects: 2388
Study 29676824 — intervention group
Group type: COMPARATOR
Intervention: Placebo with brief behavioural support
Number of subjects: 2388
Study 27125590 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical S. ebulus gel, applied three times a day for 4 weeks
Number of subjects: 79
Study 27125590 — intervention group
Group type: COMPARATOR
Intervention: 1% diclofenac gel, applied three times a day for 4 weeks
Number of subjects: 79
Study 24896807 — intervention group
Group type: EXPERIMENTAL
Intervention: Kre-Celazine(®)
Number of subjects: 16
Study 22772746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home aftercare
Number of subjects: 130
Study 22772746 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 130
Study 20300778 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution with 1% glucose (Group G)
Number of subjects: 31
Study 20300778 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer's solution without glucose (Group R)
Number of subjects: 31
Study 18525137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-coaching intervention (10 sessions)
Number of subjects: 24
Study 16112300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy
Number of subjects: 101
Study 16112300 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 101
Study 12472703 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (group C: n = 20; ropivacaine 0.2%, 1 ml.kg‐1 + clonidine 2 micro g.kg‐1)
Number of subjects: 40
Study 12472703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block (group I: n = 20; ropivacaine 0.2%, 0.4 ml.kg‐1 + clonidine 2 micro g.kg‐1)
Number of subjects: 40
Study 10221346 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (enalapril maleate) alone (group I)
Number of subjects: 18
Study 10221346 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril maleate) plus spironolactone (25 mg/d) (group II)
Number of subjects: 18
Study 7590642 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 150 micrograms desogestrel (EE/DG)
Number of subjects: 0
Study 7590642 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 3-keto-desogestrel (EE/KDG)
Number of subjects: 0
Study 7590642 — intervention group
Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 0
Study 2126985 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma (rIFN gamma) at doses escalating from 0.01 mg/m2 to 5 mg/m2, given by intravenous bolus every 72 hours for 15 days
Number of subjects: 29
Study 7025261 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 300 mg/d
Number of subjects: 0
Study 7025261 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg/d
Number of subjects: 0
Study 30152252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic treatment
Number of subjects: 400
Study 30152252 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic treatment
Number of subjects: 400
Study 27921448 — intervention group
Group type: EXPERIMENTAL
Intervention: Li maneuver
Number of subjects: 113
Study 27921448 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver
Number of subjects: 113
Study 26911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-setting manipulation (flexion top spin and lock bone-setting manipulation of cervical spine), treated once every two days for 20 days
Number of subjects: 320
Study 26911112 — intervention group
Group type: COMPARATOR
Intervention: Manipulation of reposition cervical spine by rotation, treated once every two days for 20 days
Number of subjects: 320
Study 23343564 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) using 12-lead ECG and hand-held ECG recording for 2 weeks.
Number of subjects: 848
Study 23343564 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) using hand-held ECG recording.
Number of subjects: 848
Study 23343564 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) leading to oral anticoagulation treatment.
Number of subjects: 848
Study 23343564 — intervention group
Group type: EXPERIMENTAL
Intervention: Known atrial fibrillation (AF) patients not on oral anticoagulation treatment.
Number of subjects: 848
Study 22589265 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg
Number of subjects: 783
Study 19359633 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP group (n=53)
Number of subjects: 103
Study 19359633 — intervention group
Group type: COMPARATOR
Intervention: Control group (education protocol, n=50)
Number of subjects: 103
Study 17294437 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular detection of luminal bacterial species
Number of subjects: 75
Study 17294437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanisms of innate immune and epithelial responses to bacteria
Number of subjects: 75
Study 17294437 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation of inflammation by innate and acquired immune cells
Number of subjects: 75
Study 15452780 — intervention group
Group type: EXPERIMENTAL
Intervention: Detachable snares
Number of subjects: 488
Study 15452780 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection (0.01% solution)
Number of subjects: 488
Study 15452780 — intervention group
Group type: COMPARATOR
Intervention: Conventional snare polypectomy without preventive measures
Number of subjects: 488
Study 15452780 — intervention group
Group type: EXPERIMENTAL
Intervention: Detachable snares (in polyps >= 2 cm)
Number of subjects: 488
Study 15452780 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection (in polyps >= 2 cm)
Number of subjects: 488
Study 15452780 — intervention group
Group type: COMPARATOR
Intervention: Conventional snare polypectomy without preventive measures (in polyps >= 2 cm)
Number of subjects: 488
Study 11255206 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Group (HEP)
Number of subjects: 105
Study 11255206 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 105
Study 9236425 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic volume index (ESVI) measured at 90 to 180 minutes into thrombolytic therapy for MI
Number of subjects: 41021
Study 9236425 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables tested in stepwise logistic regression analysis
Number of subjects: 41021
Study 8426717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% fluocinonide
Number of subjects: 40
Study 8426717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2890522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 2395
Study 2890522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2395
Study 30503723 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Seldinger technique with combination CVC device
Number of subjects: 0
Study 30503723 — intervention group
Group type: COMPARATOR
Intervention: Modified Seldinger technique with standard CVC kit
Number of subjects: 0
Study 27819431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drinks (AmED)
Number of subjects: 16
Study 27819431 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 16
Study 27819431 — intervention group
Group type: COMPARATOR
Intervention: Energy drink conditions
Number of subjects: 16
Study 24871705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg Methylnaltrexone (MTNX)
Number of subjects: 29
Study 24871705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.225 mg/kg Methylnaltrexone (MTNX)
Number of subjects: 29
Study 24871705 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 29
Study 24871705 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.143 mg/kg Morphine sulfate
Number of subjects: 29
Study 23341547 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention
Number of subjects: 45
Study 23341547 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 45
Study 20661660 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg Se as Se-rich yeast)
Number of subjects: 42
Study 20661660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (baker's yeast)
Number of subjects: 42
Study 19204390 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 ppm NaF toothpaste without postbrushing water rinsing
Number of subjects: 26
Study 19204390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450 ppm NaF toothpaste with water rinsing
Number of subjects: 26
Study 19204390 — intervention group
Group type: COMPARATOR
Intervention: 5,000 ppm NaF toothpaste with postbrushing water rinsing
Number of subjects: 26
Study 19204390 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm NaF toothpaste without water rinsing
Number of subjects: 26
Study 19204390 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 5,000 ppm without rinsing and 1,450 ppm with rinsing
Number of subjects: 26
Study 19204390 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fluoride concentration per unit weight of plaque
Number of subjects: 26
Study 16881422 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of misoprostol applied three times in a 6 hour interval
Number of subjects: 125
Study 16881422 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms of misoprostol applied three times in a 6 hour interval
Number of subjects: 125
Study 16881422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between the two dosages)
Number of subjects: 125
Study 15658647 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1.2 g per day for 12 weeks
Number of subjects: 105
Study 15658647 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 105
Study 11820258 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (l-AmB) prophylaxis, 1 mg kg(‐1) body weight, thrice-weekly
Number of subjects: 0
Study 11820258 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (early intervention arm)
Number of subjects: 0
Study 11820258 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (l-AmB) prophylaxis
Number of subjects: 0
Study 9668868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (education + supervised exercise training)
Number of subjects: 59